Pantel: Onto matching genotype/phenotype, mentions DEPArray. Early cancer detection: there are tumor-assoc'd mutations in aging #MDxEU17
4:24am April 12th 2017 via Hootsuite
Pantel: But in lung cancer, the number of EGFR mutations known in tissue detected in blood had sens of only 65% #MDxEU17
4:23am April 12th 2017 via Hootsuite
Pantel: Tissue biopsy vs plasma DNA analysis - '14 ref https://t.co/Z49M2iumCr this was for EGFR L858R and T790M, good spec/sens #MDxEU17
4:21am April 12th 2017 via Hootsuite
Pantel: Now looking at AR-V7, CK19 status (unpublished). Mutations relevant to Rx -(moving onto ctDNA) #MDxEU17
4:18am April 12th 2017 via Hootsuite
Pantel: Further characterization, via both EpCAM and Parsortix '16 ref https://t.co/oua7uOTFA5 #MDxEU17
4:17am April 12th 2017 via Hootsuite
Pantel: Blocking Ab - one of the top innovations of the decade. PD-L1 showed in mBC CTCs https://t.co/gr5HbEAOSO #MDxEU17
4:16am April 12th 2017 via Hootsuite
Pantel: CTC characterization is ID of targets, and ID resistance mechanisms. PD1-PD-L1 mediated immune blockade as cancer target #MDxEU17
4:14am April 12th 2017 via Hootsuite
Pantel: 2K pts, analysis of CTCs in EU, of metastatic breast cancer. '14 ref https://t.co/knAAvDdzBE #MDxEU17
Pantel: In Br ca, shows K-M curves, very promising, 'early days'. Monitoring Rx response from '13 NEJM https://t.co/RKe1oi2TNb #MDxEU17
4:12am April 12th 2017 via Hootsuite
Pantel: EpCAM+/CK+ CTCs are assoc' with poor prognosis in advanced cancers. ERA-NET TRANScan for Pr Ca https://t.co/pyO1f6ZbHi #MDxEU17
4:11am April 12th 2017 via Hootsuite
Pantel: Recent review https://t.co/4HE7Skj540 supporting the 'complementary' concept between liquid and invasive biopsy #MDxEU17
4:10am April 12th 2017 via Hootsuite
Pantel: Can get representative information from metastatic cells; CTC/ctDNA a complement to invasive biopsy #MDxEU17
4:07am April 12th 2017 via Hootsuite
Pantel: A growing concetp - across CTC, ctDNA, and exosomes. Needle biopsies are invasive; intra-tumor heterogeneity a problem #MDxEU17
Klaus Pantel (Hamburg-Eppendorf GE) Clinical applications of liquid biopsy - potential and challenges #MDxEU17
4:05am April 12th 2017 via Hootsuite
Q: Is an effort to drive sens lower? Schlange: What TracerX is doing; case studies are good, but larger cohorts needed. #MDxEU17
1:03pm April 11th 2017 via Hootsuite
Schlange: Need to have a workflow from pt sample to data back to physician. Impt for a workflow for clinical implementation #MDxEU17
12:58pm April 11th 2017 via Hootsuite
Schlange: Key issue for liq biopsy is clinical utility. And pre-analytical req's are needed. To use standards 'as much as possible' #MDxEU17
Schlange: For circulating miRNA markers, may even be more challenging, even the right time of the day for sample collection #MDxEU17
12:57pm April 11th 2017 via Hootsuite
Schlange: Shows extensive list of standards and technologies, incl fragmentase from NEB, or Sequins from AUS, or IDT synthetics #MDxEU17
12:56pm April 11th 2017 via Hootsuite
Schlange: Efficiency of extraction, use of standards for NGS panels (@SeraCare) and need for bioinformatics stnds #MDxEU17
12:55pm April 11th 2017 via Hootsuite
Schlange: Other initiatives - IBLL/LIH, SPIDIA-4P, IQNPath. (He lists website links.) ctDNA RING studies - tube selection #MDxEU17
12:54pm April 11th 2017 via Hootsuite
Schlange: ISO guidleines - 2-8C, but less hemolysis at RT. Spin 2x is better, may be less feasible clinically #MDxEU17
12:53pm April 11th 2017 via Hootsuite
Schlange: Little data on what blood volumes people can get in the first place. From cobas - similar percentages. CAPP-Seq to 0.02% #MDxEU17
12:52pm April 11th 2017 via Hootsuite
Schlange: Prior was for metastatic. For localized - 30-50%. NSCLC - 60^ of Stg I/II, can get mean AF 2%. #MDxEU17
12:51pm April 11th 2017 via Hootsuite
Schlange: Showed slide from Bettegowda '14 STM 85-95% of cancer cases where ctDNA is detected (CRC, Panc, Breast, Gastric) #MDxEU17
12:49pm April 11th 2017 via Hootsuite
Schlange: Most impt - repro. Shows data of recovery with CellSerch, negative recovery of EpCAM neg, and Siemens tech #MDxEU17
12:48pm April 11th 2017 via Hootsuite
Schlange: CTC RING study - spike-in samples shipped to 3 sites, yield, cp to CellSearch. Heterogeneity; purify (WBC backgnd) #MDxEU17
12:47pm April 11th 2017 via Hootsuite
Schlange: Wanted to have no new assays - just how to best combine tech and use them clinically. #MDxEU17
12:46pm April 11th 2017 via Hootsuite
Schlange: Molecular char of NSCLC cell lines - ID a panel of cell lines at different EpCAM, EGFR, KRAS status #MDxEU17
12:45pm April 11th 2017 via Hootsuite
Schlange: Feels that the FDA is keenly interested, wants to be involved at the advisory level. #MDxEU17
12:44pm April 11th 2017 via Hootsuite
Schlange: Protocols, output formats, results and comparing them - all different. 1.5y ago a "critical path innovation mtg" #MDxEU17
Schlange: Lung ca and HER2 Rx resistant BC has started. Same technology at different sites. #MDxEU17
12:43pm April 11th 2017 via Hootsuite
Schlange: need to look at primary tumor, clin outcome, treatment response, ctDNA status. Want to prove clin utilty #MDxEU17
12:42pm April 11th 2017 via Hootsuite
Schlange: Ultimate proof may be from genetic information at single-cell level. SOP from pre-analytic sample handling. #MDxEU17
12:41pm April 11th 2017 via Hootsuite
Schlange: 2nd indication: HER2+, treatment refractory breast cancer. CellSearch already approved. Est criteria for detection #MDxEU17
12:40pm April 11th 2017 via Hootsuite
Schlange: 3 ongoing clinical trials - TracerX, Netherlands Trial, EORTC Spectralung. Larger population of samples. #MDxEU17
12:39pm April 11th 2017 via Hootsuite
Schlange: 35 partners, companies in US, Singapore. One indication: NSCLC, easy to agree on. Est of 7.5mL, only 10% will have >1CTC #MDxEU
Schlange: IMI is meeting high unmet need, Pharma + EU commission. 3.3B € funding through 2024. #MDxEU17
12:37pm April 11th 2017 via Hootsuite
Schlange: Gilupi with a wire collection device, diagnostic apheresis. Goal: >50 living CTCs in >50% of pts #MDxEU17
12:35pm April 11th 2017 via Hootsuite
Schlange: 1/2 of drugs have assoc'd biomarker. CTC for mBC, mMelanoma, mCRC. More markers - Seimens, Apocell, Fluxion, Biocept #MDxEU17
12:34pm April 11th 2017 via Hootsuite
Schlange: Multi-center studies need short proc time, reasonable costs. CTCs have one approved test (CellSearch) #MDxEU17
12:33pm April 11th 2017 via Hootsuite
Schlange: Want early dx, pt stratification; early signs of efficacy. Early ID of drug resist. #MDxEU17
12:32pm April 11th 2017 via Hootsuite
Schlange: The int'l coordinator of IMI's CANCER ID: website https://t.co/hS2PKXuDOK CTCs, ctDNA, miRNA as blood-based biomarkers #MDxEU17
12:31pm April 11th 2017 via Hootsuite
Thomas Schlange (Bayer DE) Standardization of ctDNA analysis for use in the clinical setting under the umbrella of CANCER-ID #MDxEU17
12:29pm April 11th 2017 via Hootsuite
Q: Where would neg samples come from in hosp setting? Habermann: There are cohorts available from biobanks, also healthy pts #MDxEU17
12:28pm April 11th 2017 via Hootsuite
Habermann: (Review article '15 of biobanking storage conditions https://t.co/5b3Qe8J5fy -80C not good for RNA?) #MDxEU17
12:26pm April 11th 2017 via Hootsuite
Habermann: Patient consent, biobank's data updated by the clinical phenotyping data (2K parameters) #MDxEU17
12:22pm April 11th 2017 via Hootsuite
Habermann: 3 international organizations for biobanking: ESBB, BBMRI, ISBER, first int'l meeting in Stockholm in Sept '17. #MDxEU17
12:18pm April 11th 2017 via Hootsuite
Habermann: Low degree of standardization for isolation, assessment. Could be implemented in biobanking workflows. #MDxEU17
12:16pm April 11th 2017 via Hootsuite
Habermann: #MDxEU17 Exosome enrichment review '16 https://t.co/KfNa8PNZbL Exoquick not evaluated before, shows data via PCA
12:15pm April 11th 2017 via Hootsuite
